Overview

Innoviva, Inc. is a company with a portfolio of royalties that include respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR®/BREO® ELLIPTA® (fluticasone furoate/ vilanterol, “FF/VI”), ANORO® ELLIPTA® (umeclidinium bromide/ vilanterol, “UMEC/VI”) and TRELEGY® ELLIPTA® (the combination FF/UMEC/VI).

Under the Long-Acting Beta2 Agonist (“LABA”) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva is also entitled to 15% of royalty payments made by GSK under its agreements originally entered into with us, and since assigned to Theravance Respiratory Company, LLC (“TRC”), relating to TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered and developed in the future under the LABA Collaboration Agreement and the Strategic Alliance Agreement with GSK (referred to herein as the “GSK Agreements”), which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.

ANORO®, RELVAR®, BREO®, TRELEGY® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

Royalties Earned

Royalties Earned

Press Releases

Date Title and Summary
Toggle Summary Innoviva Reports Second Quarter 2020 Financial Results
Royalties increased by 7% to $72.4 million in the second quarter of 2020, compared to the same quarter in 2019. Pavel Raifeld named as Chief Executive Officer. Invested $35 million into common stock and warrants of Entasis Therapeutics Holding Inc. (NASDAQ: ETTX), a leader in anti-infectives
Toggle Summary Entasis Therapeutics Completes Closing of Second Tranche of $35M Private Placement with Innoviva
WALTHAM, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the closing of the second tranche of the $35
Toggle Summary Innoviva Names Pavel Raifeld as Chief Executive Officer
Pavel Raifeld to continue the implementation of the Company’s strategy and focus on value creation for shareholders BURLINGAME, Calif. --(BUSINESS WIRE)--May 21, 2020-- Innoviva, Inc. (NASDAQ: INVA) (“Innoviva”) today announced the appointment of Pavel Raifeld as Chief Executive Officer effective
Toggle Summary Innoviva Reports First Quarter 2020 Financial Results
Total net revenue increased by 43% to $78.7 million in the first quarter of 2020, compared to the same quarter in 2019. Income before income taxes increased by 96% to $94.9 million in the first quarter of 2020, compared to the same quarter in 2019. BURLINGAME, Calif. --(BUSINESS WIRE)--Apr.
Presentations & Events
There are currently no events to display.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Contact

Toll-Free
877-202-1097

Innoviva Investor Relations & Media
Sloane and Company
212-486-9500

For business development inquiries,
please contact investor.relations@inva.com.